Recombinant bacillus Calmette-Guerin in urothelial bladder cancer immunotherapy: current strategies

被引：8

作者：

Wang, Yonghua ^{[1
]}

Yang, Meng ^{[1
]}

Yu, Qinchao ^{[1
]}

Yu, Lun ^{[1
]}

Shao, Shixiu ^{[1
]}

Wang, Xinsheng ^{[1
]}

机构：

[1] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266071, Peoples R China

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 01期

基金：

中国国家自然科学基金;

关键词：

bacillus Calmette-Guerin; BCG; immunotherapy; intravesical therapy; recombinant BCG; urothelial bladder cancer; TRANSITIONAL-CELL CARCINOMA; EXPRESSING PERTUSSIS TOXIN; GAMMA-INDUCING FACTOR; MYCOBACTERIUM-BOVIS; IFN-GAMMA; INTRAVESICAL THERAPY; DNA VACCINES; MITOMYCIN-C; TH1-STIMULATING CYTOKINES; PLUS INTERFERON-ALPHA-2B;

D O I：

10.1586/14737140.2015.961430

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bacillus Calmette-Guerin (BCG) has been used in the intravesical treatment of urothelial bladder cancer (UBC) for three decades. Despite its efficacy, intravesical BCG therapy is associated with some limitations such as side effects and BCG failure, which have inspired multiple ways to improve it. Recent advances have focused on recombinant BCG (rBCG) which provides a novel tactic for modification of BCG. To date, a number of rBCG strains have been developed and demonstrated to encourage efficacy and safety in preclinical and clinical studies. This review summarizes current rBCG strategies, concerns and future directions in UBC immunotherapy with an intention to encourage further research and eventually to inform clinical decisions.

引用

页码：85 / 93

页数：9

共 97 条

[81]

Slaton JW, 1999, CLIN CANCER RES, V5, P2726

[82]

Slobbe L, 1999, IMMUNOLOGY, V96, P517, DOI 10.1046/j.1365-2567.1999.00702.x

[83] THE CRYSTAL-STRUCTURE OF PERTUSSIS TOXIN [J].

STEIN, PE ;

BOODHOO, A ;

ARMSTRONG, GD ;

COCKLE, SA ;

KLEIN, MH ;

READ, RJ .

STRUCTURE, 1994, 2 (01) :45-57

[84] Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin [J].

Thalmann, GN ;

Sermier, A ;

Rentsch, C ;

Möhrle, K ;

Cecchini, MG ;

Studer, UE .

JOURNAL OF UROLOGY, 2000, 164 (06) :2129-2133

[85] Costimulatory Molecule B7-H1 on the Immune Escape of Bladder Cancer and Its Clinical Significance [J].

Wang, Yonghua ;

Zhuang, Qianyuan ;

Zhou, Siwei ;

Hu, Zhiquan ;

Lan, Ruzhu .

JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2009, 29 (01) :77-79

[86] Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder [J].

Weiss, GR ;

O'Donnell, MA ;

Loughlin, K ;

Zonno, K ;

Laliberte, RJ ;

Sherman, ML .

JOURNAL OF IMMUNOTHERAPY, 2003, 26 (04) :343-348

[87] Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells [J].

Xu, DM ;

Chan, WL ;

Leung, BP ;

Hunter, D ;

Schulz, K ;

Carter, RW ;

McInnes, IB ;

Robinson, JH ;

Liew, FY .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (08) :1485-1492

[88] Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2 [J].

Yamada, H ;

Matsumoto, S ;

Matsumoto, T ;

Yamada, T ;

Yamashita, U .

JOURNAL OF UROLOGY, 2000, 164 (02) :526-531

[89] Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin [J].

Young, S ;

O'Donnell, M ;

Lockhart, E ;

Buddle, B ;

Slobbe, L ;

Luo, Y ;

De Lisle, G ;

Buchan, G .

IMMUNOLOGY AND CELL BIOLOGY, 2002, 80 (03) :209-215

[90] Immunotherapy for orthotopic murine bladder cancer using bacillus Calmette-Guerin recombinant protein Mpt-64 [J].

Yu, Dah-Shyong ;

Lee, Chi-Feng ;

Chang, Sun-Yran .

JOURNAL OF UROLOGY, 2007, 177 (02) :738-742

← 1 2 3 4 5 6 7 8 9 10 →